$DROR
Dror Ortho-Design, Inc.

2024 Q4 Form 10-Q Financial Statement

#000121390024098394 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $451.0K
YoY Change 82.58%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.302M
YoY Change 134.39%
Operating Profit -$1.302M
YoY Change 134.39%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$525.2K
YoY Change -28894.46%
Pretax Income -$1.827M
YoY Change 230.05%
Income Tax
% Of Pretax Income
Net Earnings -$1.827M
YoY Change 230.05%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 957.0M shares 495.5M shares
Diluted Shares Outstanding 738.3M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $1.143M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.242M
YoY Change -70.16%
LONG-TERM ASSETS
Property, Plant & Equipment $25.38K
YoY Change 916.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $25.38K
YoY Change 916.71%
TOTAL ASSETS
Total Short-Term Assets $1.242M
Total Long-Term Assets $25.38K
Total Assets $1.267M
YoY Change -69.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $84.68K
YoY Change 1353.48%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $887.9K
YoY Change -9.47%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities $5.126K
YoY Change 1248.95%
Total Long-Term Liabilities $5.126K
YoY Change 1248.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $887.9K
Total Long-Term Liabilities $5.126K
Total Liabilities $893.0K
YoY Change -8.98%
SHAREHOLDERS EQUITY
Retained Earnings -$18.37M
YoY Change 60.21%
Common Stock $95.70K
YoY Change 93.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $374.5K
YoY Change
Total Liabilities & Shareholders Equity $1.267M
YoY Change -69.57%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$1.827M
YoY Change 230.05%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
738290665 shares
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-51783
dei Entity Registrant Name
EntityRegistrantName
Dror Ortho-Design, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0461778
dei Entity Address Address Line1
EntityAddressAddressLine1
Shatner Street 3
dei Entity Address City Or Town
EntityAddressCityOrTown
Jerusalem
dei Entity Address Country
EntityAddressCountry
IL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
N/A
dei City Area Code
CityAreaCode
+972
dei Local Phone Number
LocalPhoneNumber
(0)74-700-6700
dei Security12b Title
Security12bTitle
None
dei No Trading Symbol Flag
NoTradingSymbolFlag
true
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
956997116 shares
CY2024Q3 us-gaap Cash
Cash
1143269 usd
CY2023Q4 us-gaap Cash
Cash
3347843 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
98830 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
114100 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
1242099 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
3461943 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25377 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2328 usd
CY2024Q3 us-gaap Assets
Assets
1267476 usd
CY2023Q4 us-gaap Assets
Assets
3464271 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
84680 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
106833 usd
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
283208 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
190271 usd
CY2024Q3 dror Registration Rights Agreement Liability
RegistrationRightsAgreementLiability
520000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
887888 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
297104 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5126 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5243 usd
CY2024Q3 us-gaap Liabilities
Liabilities
893014 usd
CY2023Q4 us-gaap Liabilities
Liabilities
302347 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
12500000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
12500000 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
5847937 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10463363 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
585 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
1047 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3254475740 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
956997116 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
956997116 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
495454546 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
495454546 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
95699 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
49545 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
18651071 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
16842037 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-18372893 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13730705 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
374462 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3161924 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1267476 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3464271 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
451030 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
325360 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1213903 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
764721 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
307593 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
227484 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1026431 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
543929 usd
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
543101 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2516 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1854726 usd
us-gaap Share Based Compensation
ShareBasedCompensation
12636 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
1301724 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
555360 usd
us-gaap Operating Expenses
OperatingExpenses
4095060 usd
us-gaap Operating Expenses
OperatingExpenses
1321286 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1301724 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-555360 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4095060 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1321286 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5211 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1824 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-27128 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16364 usd
CY2024Q3 dror Registration Rights Agreement Expense
RegistrationRightsAgreementExpense
520000 usd
dror Registration Rights Agreement Expense
RegistrationRightsAgreementExpense
520000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-525211 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1824 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-547128 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
16364 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1826935 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-553536 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4642188 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1304922 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1826935 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-553536 usd
us-gaap Net Income Loss
NetIncomeLoss
-4642188 usd
us-gaap Net Income Loss
NetIncomeLoss
-1304922 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
738290665 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
309567766 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
309567766 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
576990761 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
576990761 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
230124665 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
230124665 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3161924 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
537197 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1308463 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2390658 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
774428 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1506790 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1658296 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
543101 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1826935 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
374462 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
596076 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
5032 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-465604 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
135504 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
5088 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-285782 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-145190 usd
CY2023Q3 us-gaap Partners Capital Account Private Placement Of Units
PartnersCapitalAccountPrivatePlacementOfUnits
4653204 usd
CY2023Q3 dror Stock Issued During Period Value Reverse Recapitalization
StockIssuedDuringPeriodValueReverseRecapitalization
-773266 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2516 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-553536 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
3183728 usd
us-gaap Net Income Loss
NetIncomeLoss
-4642188 usd
us-gaap Net Income Loss
NetIncomeLoss
-1304922 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1854726 usd
us-gaap Share Based Compensation
ShareBasedCompensation
12636 usd
us-gaap Depreciation
Depreciation
2800 usd
us-gaap Depreciation
Depreciation
502 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-15270 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
40006 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-22153 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-56896 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
92937 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-114529 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
520000 usd
dror Increase Decrease In Founders Claim Accrual
IncreaseDecreaseInFoundersClaimAccrual
-240000 usd
dror Increase Decrease In Accrued Royalties
IncreaseDecreaseInAccruedRoyalties
6438 usd
dror Increase Decrease In Accrued Severance
IncreaseDecreaseInAccruedSeverance
117 usd
dror Increase Decrease In Accrued Severance
IncreaseDecreaseInAccruedSeverance
33 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2178725 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1736810 usd
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
25849 usd
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
-17966 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25849 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
17966 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
4695336 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4695336 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2204574 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2976492 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3347843 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1039059 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1143269 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4015551 usd
us-gaap Stock Issued1
StockIssued1
20231 usd
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
791232 usd
dror Noncash Or Part Noncash Acquisition Accrued Transaction Costs
NoncashOrPartNoncashAcquisitionAccruedTransactionCosts
42132 usd
CY2023Q3 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
235089 shares
CY2023Q3 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
106782187 shares
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-18372893 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates and Assumptions</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates or assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could vary from those estimates. Management utilizes various other estimates, including but not limited to Registration Rights Agreement liability, accrued royalties, accrued expenses, the valuation of stock-based compensation, the valuation allowance for deferred tax assets and other contingencies. The results of any changes in accounting estimates are reflected in the financial statements in the period in which the changes become evident. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the period that they are determined to be necessary.</span></p>
CY2024Q3 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
3.71 pure
CY2023Q4 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
3.627 pure
CY2024Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
0 usd
CY2023Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
145168 usd
CY2024Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1091993 usd
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
2935078 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1744346942 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2174312803 shares
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reclassification</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expenses amounting to $71,071 and $168,113 were reclassified to research and development expenses for the three and nine months ended September 30, 2023, respectively, to conform with current period presentation. General and administrative expenses amounting to $2,516 and $12,636 were reclassified to stock-based compensation expenses for the three and nine months ended September 30, 2023, respectively, to conform with current period presentation. The reclassifications had no effect on the net loss for the nine months ended September 30, 2023.</span></p>
CY2023Q3 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
71071 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
168113 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2516 usd
us-gaap Share Based Compensation
ShareBasedCompensation
12636 usd
CY2021Q4 us-gaap Payments For Repurchase Of Private Placement
PaymentsForRepurchaseOfPrivatePlacement
3000000 usd
CY2024Q3 us-gaap Product Warranty Liquidation Proceeds Percentage
ProductWarrantyLiquidationProceedsPercentage
0.01 pure
us-gaap Credit Derivative Liquidation Proceeds Percentage
CreditDerivativeLiquidationProceedsPercentage
0.18 pure
CY2024Q3 us-gaap Investment Interest Rate
InvestmentInterestRate
0.501 pure
us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
520000 usd
dror Percentage Of Royalty Payment
PercentageOfRoyaltyPayment
0.03 pure
dror Maximum Percentage Of Grants Provided For Royalty Payment
MaximumPercentageOfGrantsProvidedForRoyaltyPayment
1 pure
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Common Stock are entitled to vote on a 1 share/1 vote basis
CY2023Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.033
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
35814 usd
dror Aggregate Fair Value
AggregateFairValue
35814 usd
dror Exercise Price Of The Warrants Percentage
ExercisePriceOfTheWarrantsPercentage
3 pure
dror Minimum Trading Volume Of Common Stock Each Trading Day Condition For Warrant Redemption
MinimumTradingVolumeOfCommonStockEachTradingDayConditionForWarrantRedemption
500000 usd
CY2024Q3 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
0.001
CY2024Q3 us-gaap Shares Held In Employee Stock Option Plan Allocated
SharesHeldInEmployeeStockOptionPlanAllocated
163142084 shares
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4261809 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
21122239 shares
CY2024Q2 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
0.0037
CY2024Q2 dror Vested Immediately Grant And Terminate
VestedImmediatelyGrantAndTerminate
P10Y
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
543101 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2516 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1854726 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12636 usd
CY2022Q2 dror Payment Of Cash Fee Received
paymentOfCashFeeReceived
3500 ils
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2610 shares
CY2022Q2 us-gaap Stockholders Equity Note Changes In Capital Structure Subsequent Changes To Number Of Common Shares
StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares
9597675 shares
CY2024Q1 dror Payment Of Cash Fee Received
paymentOfCashFeeReceived
5000 usd
CY2024Q1 us-gaap Proceeds From Fees Received
ProceedsFromFeesReceived
55000 usd
CY2023Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
145000 usd
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10454500 shares
CY2023Q3 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
0.033
CY2023Q3 us-gaap Dividends Share Based Compensation Cash
DividendsShareBasedCompensationCash
14500 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Expiration Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
2024-07-15
CY2024Q2 us-gaap Product Warranty Liquidation Proceeds Amount
ProductWarrantyLiquidationProceedsAmount
35814 usd
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 dror Registration Rights Agreement Liability
RegistrationRightsAgreementLiability
usd
CY2023Q3 dror Registration Rights Agreement Expense
RegistrationRightsAgreementExpense
usd
dror Registration Rights Agreement Expense
RegistrationRightsAgreementExpense
usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2024Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
CY2023Q1 dror Stock Issued During Period Value Return Of Founders Shares To The Company As Part Of Claim Settlement
StockIssuedDuringPeriodValueReturnOfFoundersSharesToTheCompanyAsPartOfClaimSettlement
usd
CY2023Q3 us-gaap Stock Issued During Period Shares Treasury Stock Reissued
StockIssuedDuringPeriodSharesTreasuryStockReissued
shares
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
usd
dror Increase Decrease In Founders Claim Accrual
IncreaseDecreaseInFoundersClaimAccrual
usd
dror Increase Decrease In Accrued Royalties
IncreaseDecreaseInAccruedRoyalties
usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
us-gaap Stock Issued1
StockIssued1
usd
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
usd
dror Noncash Or Part Noncash Acquisition Accrued Transaction Costs
NoncashOrPartNoncashAcquisitionAccruedTransactionCosts
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001282980

Files In Submission

Name View Source Status
0001213900-24-098394-index-headers.html Edgar Link pending
0001213900-24-098394-index.html Edgar Link pending
0001213900-24-098394.txt Edgar Link pending
0001213900-24-098394-xbrl.zip Edgar Link pending
dror-20240930.xsd Edgar Link pending
ea0220808-10q_drorortho.htm Edgar Link pending
ea0220808ex31-1_drorortho.htm Edgar Link pending
ea0220808ex31-2_drorortho.htm Edgar Link pending
ea0220808ex32-1_drorortho.htm Edgar Link pending
ea0220808ex32-2_drorortho.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
dror-20240930_def.xml Edgar Link unprocessable
dror-20240930_lab.xml Edgar Link unprocessable
dror-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ea0220808-10q_drorortho_htm.xml Edgar Link completed
dror-20240930_cal.xml Edgar Link unprocessable